Table 1.

Characteristics of 12 patients with atypical exanthemas and eosinophilia

	Case 1	Case 2	Case 3	Case 4	Case 5	Case 6	Case 7	Case 8	Case 9	Case 10	Case 11	Case 12
Demographics	Female, 64 y.o. Asthma, HT	Male, 79 y.o. HT, DL, CKD	Female, 74 y.o.	Male, 47 y.o.	Female, 74 y.o. HT, DL	Female, 61 y.o. HT, DL	Male, 67 y.o. HT, DL, CKD	Male, 76 y.o. HT	Female, 61 y.o. Asthma	Male, 71 y.o. HT	Male, 59 y.o.	Female 62 y.o. HT, DL
Treatment received for COVID‐19	HC, LP/RT, IFN‐β, CF	HC, LP/RT, IFN‐β, CF	HC, LP/RT, IFN‐β, CF	HC LP/RT, IFN‐β, CF, AZ, DXM, TZ	HC, LP/RT, IFN‐β, AZ, MP	HC LP/RT, IFN‐β, CF,	HC LP/RT, IFN‐β, MP, piperacillin/ tazobactam	HC, LP/RT, CF, AZ, MP	HC, LP/RT, CF	HC LP/RT, IFN‐β, CF, AZ, DXM TZ, RDS	HC LP/RT, IFN‐β, CF, DXM, TZ	HC LP/RT, CF, AZ, MP, TZ
Time from hospital admission to exanthema onset	14 days	28 days	23 days	24 days	18 days	10 days	19 days	19 days	22 days	21 days	26 days	21 days
COVID disease status at exanthema onset	Improvement	Worsening. Reintroduction of drugs	Improvement	Improvement	Improvement	Improvement	Worsening	Improvement	Improvement	Improvement	Improvement	Improvement
Clinical presentation	Fever Generalized maculopapular confluent exanthema Targetoid lesions Facial oedema Itch +++	No fever Generalized maculopapular confluent exanthema Violaceous lesions Targetoid lesions Itch +	Fever Generalized maculopapular confluent exanthema Violaceous lesions Targetoid lesions Facial oedema Itch ++	No fever Generalized maculopapular confluent exanthema Violaceous lesions Targetoid lesions Itch ++	No fever Generalized maculopapular confluent exanthema Itch ++	No fever Generalized maculopapular confluent exanthema Itch +++	No fever Generalized maculopapular confluent exanthema Itch ++	No fever Generalized maculopapular confluent exanthema Itch +	Low‐grade fever Generalized maculopapular confluent exanthema Violaceous lesions Facial oedema Itch ++	No fever Generalized maculopapular confluent exanthema Violaceous lesions Itch +	No fever Generalized maculopapular confluent exanthema Itch +	No fever Generalized maculopapular confluent exanthema Violaceous lesions Itch ++
Analytical results	Eos 1500/μL Lymp 3100/μL ALTa 29 U/L	Eos 1400/μL Lymp 1000/μL ALT 50 U/L	Eos 1400/μL Lymp 2600/μL ALT 56 U/L	Eos 2300/μL Lymp 2100/μL ALT 153 U/L	Eos 1200/μL Lymp 2000/μL ALT 68 U/L	Eos 800/μL Lymp 2000/μL ALT 34 U/L	Eos 1000/μL Lymp 1300/μL ALT 32 U/L	Eos 700/μL Lymp 900/μL ALT 30 U/L	Eos 1600/μL Lymp 1800μL ALT 23 U/L	Eos 900/μL Lymp 1100μL ALT 20 U/L	Eos 1000/μL Lymp 800μL ALT 36 U/L	Eos 600/μL Lymp 900/μL ALT 495 U/L
Treatment	MP (IV): 40mg BID	Prednisone (PO): 40 mg OD	MP (IV): 30 mg BID	MP (IV): 20mg OD	MP aceponate (top.) BID	MP aceponate (top.) BID	MP aceponate (top.) BID	MP aceponate (top.) BID	Prednisone (PO): 30 mg OD	MP aceponate (top.) BID	MP aceponate (top.) BID	MP (IV): 40mg BID

Reference ranges are as follows: eosinophils 0 to 500 per microlitre; lymphocytes 1300 to 1500 per microlitre and ALT 5 to 41 U/L. y.o. denotes years old, HT hypertension, DL dyslipidemia, CKD chronic kidney disease, HC hydroxychloroquine, LP/RT Lopinavir/Ritonavir, CF ceftriaxone, AZ azithromycin, MP methylprednisolone, TZ tocilizumab, RDS remdesivir Eos eosinophils, Lymp lymphocytes, IV intravenous, BID Bis in die; PO Per os, OD Omnie die.